Literature DB >> 8068309

Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.

R E Louie1, C J Galloway, M L Dumas, M F Wong, G Mitra.   

Abstract

The safety from hepatitis C virus of intravenous immunoglobulin prepared by the cold ethanol method of Cohn-Oncley is demonstrated by clearance through the manufacturing process of 9 x 10(6) plaque-forming units of bovine viral diarrhea virus used as a surrogate for hepatitis C virus. Incubation of the intravenous immunoglobulin in its final formulation at pH 4.25 for 21 days at 21 degrees C caused a 10,000-fold decrease in bovine viral diarrhea virus intentionally added and complete inactivation of 1000 chimpanzee infectious doses per ml of hepatitis C virus.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8068309     DOI： 10.1006/biol.1994.1003

Source DB:  PubMed          Journal:  Biologicals        ISSN： 1045-1056            Impact factor:   1.856


  9 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process.

Authors:  Herbert O Dichtelmüller; Eckhard Flechsig; Frank Sananes; Michael Kretschmar; Christopher J Dougherty
Journal:  Results Immunol       Date:  2012-01-16

Review 3.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

4.  Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.

Authors:  Melvin Berger; Paul J Pinciaro; Arthur Althaus; Mark Ballow; Akhilesh Chouksey; James Moy; Hans Ochs; Mark Stein
Journal:  J Clin Immunol       Date:  2009-12-08       Impact factor: 8.317

Review 5.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

Review 6.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 7.  Assessment of the viral safety of antivenoms fractionated from equine plasma.

Authors:  Thierry Burnouf; Elwyn Griffiths; Ana Padilla; Salwa Seddik; Marco Antonio Stephano; José-María Gutiérrez
Journal:  Biologicals       Date:  2004-09       Impact factor: 1.856

8.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 9.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.